Kling Biotherapeutics

Developing antibody-based drugs against targets identified using its primary B-cell selection and evolution platform.

[Kling Biotherapeutics @KlingBio_]

🚨Catch our Director Platform Development, Alessandra Villa & Senior Scientist, B Cell Platform Lead, Casper Marsman at #PEGSEurope where they will present @KlingBio_’s cutting-edge B cell technology!

🔗Full details: https://t.co/tPJaixOPnE

@CHI_Healthtech #PEGS2025

[Kling Biotherapeutics @KlingBio_]

⚠️Catch @KlingBio_’s CSO, @StefanoGulla on the latest #OptimumPerspectivesPodcast!

Stefano dives into the future of antibody-drug conjugates and how #Kling is transforming the field with its cutting-edge B cell tech.

🎧 Listen here: https://t.co/Bmx6pLGRou

[Kling Biotherapeutics @KlingBio_]

🎓ICYMI

Our proprietary B-cell platform technologies & #antibody library approach are featured in a @ScienceDirect review on tumor-targeting #antibodies and the rise of TACAs as key immunological targets.

🔗Read more: https://t.co/qi5BnVE4f9

#immunotherapy #oncology #Bcells

[Kling Biotherapeutics @KlingBio_]

🚨 Don’t miss @KlingBio_ at #BIOEurope 2025 in Vienna, Nov 3–5!

Meet CSO @StefanoGulla and Director Platform Development Alessandra Villa to learn about our function-first approach to #antibody discovery.
📱Connect via the partnering app!

#DrugDiscovery #AntibodyTherapeutics

[Kling Biotherapeutics @KlingBio_]

Catch @KlingBio_’s Casper Marsman at the Antibody Discovery Meetup in Utrecht, NL on 29 Oct where he will discuss the utilization of immortalized patient derived B cell libraries for unbiased discovery of novel therapeutic targets.

See full details here👉 https://t.co/sC8Eq0aKh6

[Kling Biotherapeutics @KlingBio_]

📰Kling Bio featured in @DDWJournal !📰

In the Vaccines & Virology feature 💉, CEO Michael Koslowski shares @KlingBio_’s function-first approach to #antibody target 🎯 discovery.

#drugdevelopment #antibodytherapeutics

Read more ➡️https://t.co/tnTjdB6i0K

[Kling Biotherapeutics @KlingBio_]

⚡News Flash⚡

Our CSO @StefanoGulla joins #BaseToBase for a special #StandUpToCancer (@SU2C @SU2CUK) episode to discuss the future of #cancer therapeutics and innovations at #KlingBio.

#SU2C @deeptech

🎧Listen here 👉 https://t.co/OslHQYlT2Z

[Kling Biotherapeutics @KlingBio_]

📢Exciting breakthrough in the fight against #SARSCoV2 variants!

Using immortalized B cell libraries + ex vivo evolution, we developed potent antibodies that neutralize key variants like EG.5.1, JN.1 & NB.1.8.1.

🧬 Read more here 👉 https://t.co/cJK037hSAh

#PandemicResponse

[Kling Biotherapeutics @KlingBio_]

🚨 CICON25 Alert! 🚨

Swing by our posters and meet Casper Marsman & Martijn Kedde from the Kling Bio Team!

📍 Details here 👉https://t.co/IYAFL4eKRJ

#drugdiscovery

[Kling Biotherapeutics @KlingBio_]

🩸This September, @KlingBio_ joins global communities to recognize #BloodCancerAwarenessMonth🩸

📊 Explore the infographic below to understand the global impact of #bloodcancers 🌍

#ThisIsBloodCancer #Immunooncology #DrugDevelopment

[Kling Biotherapeutics @KlingBio_]

🚨ICYMI – Kling Bio and @Sanofi team up to fast-track functional #antibodies!🚨

Our CEO, Michael Koslowski discusses the strategic collaboration🤝 with the @medicine_maker

#AntibodyTherapeutics #InfectiousDiseases #Bcells

Read more here ➡️https://t.co/hm0MkeoYiO

[Kling Biotherapeutics @KlingBio_]

📢 Big news from #KlingBio!

We’ve entered into a collaboration with @sanofi to accelerate discovery of potent neutralizing #antibodies using our Kling-Select platform 🔬

Read the full press release 👉https://t.co/hCqMRugef3

#KlingSelect #Bcells

[Kling Biotherapeutics @KlingBio_]

🚨 Don’t miss our CSO, @Stefano Gullà, in the next episode of the @ChineseAntibody Society Webinar series!

🗓️ Presented in English on Zoom.

👉 Register now: https://t.co/DVEDKZ1Wso

#immunooncology #antibodytherapeutics #drugdevelopment #drugdiscovery

[Kling Biotherapeutics @KlingBio_]

Following #AACR2025, @KlingBio_ 's Director of Platform Development, Alessandra Villa, shared insights with @pharmaphorum on the latest trends shaping the future of #cancer research.

👉 Read Alessandra’s key takeaways here: https://t.co/vQGsC5G8jP

#ImmunoOncology

[Kling Biotherapeutics @KlingBio_]

Learn more about #Kling's pipeline and platform technologies here👉 https://t.co/pJNgV45u0R

[Kling Biotherapeutics @KlingBio_]

For #WorldImmunizationWeek, @KlingBio_ joins @WHO in showing the world that Immunization for All is Humanly Possible❗

Discover how #Kling’s groundbreaking #Bcell technologies are helping to support and enhance global 🌍 #immunization efforts 👇

[Kling Biotherapeutics @KlingBio_]

Join Alessandra Villa, @KlingBio_’s Director of Platform Development at #AACR2025 in Chicago 💨🏙️on April 28 at 2PM CDT as she presents our first-in-class primary B-cell selection & evolution platform. Don’t miss it!

#AACR2025

[Kling Biotherapeutics @KlingBio_]

In a @DDWJournal exclusive, our CSO, @Stefano Gulla shared his insights with @MegThomasTweets on the 2025 outlook for therapeutic #antibodies

Read the full article here👉https://t.co/mDIDoa4uOw

#DrugDevelopment #DrugDiscovery #ImmunOncology

[Kling Biotherapeutics @KlingBio_]

Connect with #Kling at #ESMOTAT to learn more about our commercially validated primary B-Cell screening and immortalization platform.

@myESMO

[Kling Biotherapeutics @KlingBio_]

Our CSO, @StefanoGulla shared his insights on the latest advances in biopharma and what we can expect to see in 2025 in the latest instalment of Scrip Asks.

Read about advancements in the development of multifunctional therapeutic antibodies here: https://t.co/REJ1Vd6cio